Today's Date: February 8, 2023
Work-Life Imbalance Cited as Top Stressor for Working Women Today, 24 Seven Report Finds   •   Large Real-World, Multi-Center Study Demonstrates Platform Saves Critical Minutes in Stroke Care   •   The Future of the Web is Here: Universe Drops Radical New Brand Campaign and Expands Tools to Empower Anyone to Own Their Corner   •   Aderant Announces Strategic Partnership with Apperio   •   CCRM Fertility Announces Two New Office Locations in Washington, D.C. and Rockville, MD   •   Skillit Releases Inaugural Craft Intelligence Report; Reveals The Top Competitive Markets for Skilled Labor in 2023   •   League and HealthSparq Partner to Streamline Health Plan Member Support, Reduce Care Costs   •   Northwestern Mutual Accelerates ESG Momentum in 2022 Sustainability Report   •   INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Plug Power Inc. and Encourages Investors   •   Seda North America Awarded Great Place to Work Certification!   •   Humana and ChenMed Announce Five-Year Network Agreement   •   reVolver Podcasts Launches New Shows on Amp, the Live Radio App from Amazon   •   Chrissy Teigen Partners with Cord Blood Registry®   •   Study Shows Novel Flavoprotein Fluorescence Measure is Correlated with Age-Related Macular Degeneration (AMD) Stage   •   Fort Health – a New Model to Tackle the Youth Mental Health Crisis in Partnership with Pediatricians   •   Children's Cancer Center Announces Vantagepoint A.I. As February Partner Of The Month   •   HIGHLIGHTS ANNOUNCES LAUNCH OF KINDNESS COLLECTION DESIGNED TO CREATE CURIOUS, CREATIVE, CARING, & CONFIDENT CHILDREN   •   Research Funding Available for Preeclampsia and Related Pregnancy Disorders   •   Kessler Foundation grants nearly $1 million to expand employment opportunities for people with disabilities striving to work in   •   STAND UP TO CANCER ANNOUNCES FOUR TEAMS FOCUSED ON DIVERSITY IN EARLY PHASE CANCER CLINICAL TRIALS
Bookmark and Share

A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selecti

SEATTLE , December 05 /Businesswire/ - AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide’s ability to selectively detect Alzheimer’s disease. The novel approach detailed in "SOBA: Development and Testing of a Soluble Oligomer Binding Assay for Detection of Amyloidogenic Toxic Oligomers" allows detection of Alzheimer’s disease at all stages, including presymptomatic cases, as well as differentiation from different amyloid-related neurodegenerative diseases. The technology was developed in the Daggett lab at the University of Washington, and AltPep is a spinout developing a revolutionary platform based on this technology focusing on early detection and treatments, with the aim to change the course of amyloid diseases.

“Early diagnosis and treatment for Alzheimer’s disease and other amyloid diseases have been elusive,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “We are targeting an early molecular trigger of amyloid diseases, a goal once thought to be unattainable. Our novel peptide platform is designed to selectively bind toxic oligomers, which is like finding a needle in a haystack. AltPep’s technology is different from other approaches because it rationally targets a specific nonstandard protein structure discovered in the Daggett lab, called alpha-sheet. These toxic oligomers form both early and throughout the disease process.”

Amyloid diseases are associated with protein misfolding and aggregation of different toxic soluble oligomer proteins. For Alzheimer’s disease, the formation of toxic amyloid beta-peptide (Aβ) oligomers is an early molecular trigger before other downstream events, such as plaque deposition and abnormal tau phosphorylation, take place. The aim is to intervene early in the disease pathway, before irreparable damage occurs, estimated to begin 10-20 years before clinically evident disease. Current treatment options are deployed too late, after a patient has signs and symptoms of the disease. This study demonstrates the ability of custom-designed, alpha-sheet peptides to both neutralize and detect these toxic oligomers in cerebrospinal fluid (CSF) and blood.

“This peer-reviewed publication highlights the unique and broad potential of AltPep’s platform to target multiple amyloid diseases,” said Chad Robins, Board Member of AltPep and Co-founder and CEO of Adaptive Biotechnologies. “This is a pivotal time for the company, with groundbreaking science and a fantastic team to execute on its important mission.”

Study Results

In the study, Alzheimer’s disease detection was achieved by testing 379 human plasma samples from 310 patients. The SOBA™ assay detected Aβ toxic oligomers in patients on the Alzheimer’s disease continuum and discriminated from other forms of dementia with 99% sensitivity and specificity. In addition, the assay identified 13 samples from cognitively normal controls with high toxic oligomer levels. In subsequent years, 12 of the 13 were confirmed to progress to mild cognitive impairment (follow-up was not available for 1 individual). These results suggest that the SOBA assay can detect early Alzheimer’s disease molecular pathology prior to clinical symptoms.

To demonstrate the broader application of the technology, CSF samples from patients with Parkinson’s disease and Lewy body dementia were evaluated using the SOBA assay adapted for detection of Parkinson’s disease-associated toxic oligomers. Strong signals and good discrimination between Parkinson’s and Alzheimer’s disease patients were seen, confirming proof of concept of the platform’s modular and broad approach.

About AltPep’s SOBA Diagnostics and SOBIN Therapeutics

SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. SOBIN therapeutics are in development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases.

AltPep has received Breakthrough Designation from the FDA for its SOBA-AD diagnostic for Alzheimer’s disease. The inclusion in the FDA Breakthrough Devices Program means that AltPep can expect prioritized review of the submission of the diagnostic test.

About AltPep Corporation

AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers in order to both detect and neutralize them throughout disease progression. AltPep’s emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases on the horizon. AltPep’s goal is to change the course of these debilitating diseases that affect over a billion people around the globe.

Decades of scientific research by the Daggett Research Group at the University of Washington provided the foundation for AltPep’s innovative approach.

For more information, please visit or follow us on LinkedIn.

Reference for publication: (link live upon publication)

STORY TAGS: Washington, United States, North America, Product/Service, Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News